A Double-Blind, Placebo-Controlled, Randomized, Parallel group study evaluating the safety, Tolerability and efficacy of two different oral doses of NP031112, a GSK-3 inhibitor, versus placebo in the treatment of patients with mild - to moderate Progress
Project Leader(s): Professor David Burn
Staff Profile: Professor David Burn
Funded by: DeNDRoN/Noscira
For further infromation regarding this study please visit the CARU website.